

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE**

In re:

Apple Tree Life Sciences, Inc., *et al.*,¹

Debtors.

Chapter 11

Case No. 25-12177 (LSS)

(Jointly Administered)

**NOTICE OF DEPOSITION OF MICHAEL BLOCH PURSUANT
TO FEDERAL RULE OF CIVIL PROCEDURE 26(a)(4) AND 30(b)(1)**

Pursuant to Federal Rules of Civil Procedure (the “**Civil Rules**”) 26(a)(4) and 30(b)(1), made applicable to the above-captioned chapter 11 cases (the “**Chapter 11 Cases**”) by Federal Rules of Bankruptcy Procedure (the “**Bankruptcy Rules**”) 9014, 7026, and 7030, and the Local Rules of the United States Bankruptcy Court for the District of Delaware (the “**Local Rules**”), parties in interest Rigmora Biotech Investor One LP, by its general partner Unicorn Biotech Ventures One Ltd, and Rigmora Biotech Investor Two LP, by its general partner Unicorn Biotech Ventures Two Ltd (collectively, the “**LPs**”), by and through their undersigned counsel, will take the deposition upon oral examination of Michael Bloch in connection with all matters currently scheduled to be heard on February 25, 2026. The deposition will take place on **February 24, 2026, commencing at 9:00 a.m. Eastern Time** at the Delaware offices of Richards, Layton & Finger, P.A, 920 North King Street Wilmington, DE 19801. The deposition will take place before

¹ The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number include: Apple Tree Life Sciences, Inc. (4506); ATP Life Science Ventures, L.P. (8224); ATP III GP, Ltd. (6091); Apertor Pharmaceuticals, Inc. (3161); Initial Therapeutics, Inc. (2453); Marlinspike Therapeutics, Inc. (4757); Red Queen Therapeutics, Inc. (8563); Evercrisp Biosciences, Inc. (4437); Nine Square Therapeutics, Inc. (4503); and Nereid Therapeutics Incorporated (8493). The location of the Debtors’ service address in these chapter 11 cases is 230 Park Avenue, Suite 2800, New York, NY 10169.



251217726022200000000002

an officer authorized by law to administer oaths and will be recorded by stenographic means, audio recording, and video recording.

Dated: February 22, 2026
Wilmington, Delaware

Respectfully Submitted,

RICHARDS, LAYTON & FINGER, P.A.

DEBEVOISE & PLIMPTON LLP

/s/ Michael J. Merchant

John H. Knight (No. 3848)
Michael J. Merchant (No. 3854)
Daniel E. Kaprow (No. 6295)
Clint M. Carlisle (No. 7313)
Nicholas A. Franchi (No. 7401)
One Rodney Square
920 North King Street
Wilmington, DE 19801
Telephone: (302) 651-7700
Facsimile: (302) 651-7701
Email: knight@rlf.com
merchant@rlf.com
kaprow@rlf.com
carlisle@rlf.com
franchi@rlf.com

Shannon Rose Selden (admitted *pro hac vice*)
M. Natasha Labovitz (admitted *pro hac vice*)
William H. Taft V (admitted *pro hac vice*)
Zachary H. Saltzman (admitted *pro hac vice*)
Natascha Born (admitted *pro hac vice*)
Carl Micarelli (admitted *pro hac vice*)
Sebastian Dutz (admitted *pro hac vice*)
66 Hudson Boulevard
New York, New York 10001
Telephone: (212) 909-6000
Email: srselden@debevoise.com
nlabovitz@debevoise.com
whtaft@debevoise.com
zsaltzman@debevoise.com
nborn@debevoise.com
cmicarelli@debevoise.com
spdutz@debevoise.com

*Counsel for Rigmora Biotech Investor One LP
(by and through its general partner Unicorn
Biotech Ventures One Ltd) and Rigmora Biotech
Investor Two LP (by and through its general
partner Unicorn Biotech Ventures Two Ltd)*